^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective estrogen receptor α inhibitor

    Related drugs:
    Apply
    A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer (H3B-6545-G000-102) (NCT04288089)
    Phase 1
    Eisai Inc.
    Active, not recruiting
    Last update posted :
    03/28/2024
    Initiation :
    04/01/2020
    Primary completion :
    09/16/2022
    Completion :
    08/31/2024
    HER-2 • ER
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • H3B-6545
    Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer (H3B-6545-A001-101) (NCT03250676)
    Phase 1/2
    Eisai Inc.
    Completed
    Last update posted :
    12/25/2023
    Initiation :
    08/17/2017
    Primary completion :
    10/26/2023
    Completion :
    10/26/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation
    |
    H3B-6545
    Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (NCT04568902)
    Phase 1
    Eisai Co., Ltd.
    Active, not recruiting
    Last update posted :
    12/22/2023
    Initiation :
    09/30/2020
    Primary completion :
    08/31/2024
    Completion :
    08/31/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    H3B-6545
    Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer (NCT00166543)
    Phase 2
    SRI International
    Completed
    Last update posted :
    08/18/2015
    Initiation :
    05/01/2004
    Primary completion :
    01/01/2008
    Completion :
    01/01/2008
    ER • PGR
    |
    TAS-108